329 related articles for article (PubMed ID: 7812911)
1. Expansion of the Ki-67 proliferative compartment correlates with degree of dysplasia in Barrett's esophagus.
Hong MK; Laskin WB; Herman BE; Johnston MH; Vargo JJ; Steinberg SM; Allegra CJ; Johnston PG
Cancer; 1995 Jan; 75(2):423-9. PubMed ID: 7812911
[TBL] [Abstract][Full Text] [Related]
2. Aberrant expression of minichromosome maintenance proteins 2 and 5, and Ki-67 in dysplastic squamous oesophageal epithelium and Barrett's mucosa.
Going JJ; Keith WN; Neilson L; Stoeber K; Stuart RC; Williams GH
Gut; 2002 Mar; 50(3):373-7. PubMed ID: 11839717
[TBL] [Abstract][Full Text] [Related]
3. Anti-phosphorylated histone H3 expression in Barrett's esophagus, low-grade dysplasia, high-grade dysplasia, and adenocarcinoma.
Goodarzi M; Correa AM; Ajani JA; Swisher SG; Hofstetter WL; Guha S; Deavers MT; Rashid A; Maru DM
Mod Pathol; 2009 Dec; 22(12):1612-21. PubMed ID: 19734842
[TBL] [Abstract][Full Text] [Related]
4. Transforming growth factor-alpha, epidermal growth factor receptor, and MiB-1 expression in Barrett's-associated neoplasia: correlation with prognosis.
Yacoub L; Goldman H; Odze RD
Mod Pathol; 1997 Feb; 10(2):105-12. PubMed ID: 9127315
[TBL] [Abstract][Full Text] [Related]
5. Malignant degeneration of Barrett's esophagus: the role of the Ki-67 proliferation fraction, expression of E-cadherin and p53.
Feith M; Stein HJ; Mueller J; Siewert JR
Dis Esophagus; 2004; 17(4):322-7. PubMed ID: 15569371
[TBL] [Abstract][Full Text] [Related]
6. Malignant progression in Barrett's esophagus: pathology and molecular biology.
Mueller J; Werner M; Siewert JR
Recent Results Cancer Res; 2000; 155():29-41. PubMed ID: 10693236
[TBL] [Abstract][Full Text] [Related]
7. Immunohistological study of cell cycle-related factors, oncogene expression, and cell proliferation in adenocarcinoma developed in Barrett's esophagus.
Fujii T; Nakagawa S; Hanzawa M; Sueyoshi S; Fujita H; Shirouzu K; Yamana H
Oncol Rep; 2003; 10(2):427-31. PubMed ID: 12579284
[TBL] [Abstract][Full Text] [Related]
8. Suppression of apoptosis does not foster neoplastic growth in Barrett's esophagus.
Soslow RA; Remotti H; Baergen RN; Altorki NK
Mod Pathol; 1999 Mar; 12(3):239-50. PubMed ID: 10102608
[TBL] [Abstract][Full Text] [Related]
9. [Immunohistochemical expression of the p53 and Ki-67 proteins in Barrett's esophagus in Korea].
Kim CW; Lee BI; Kim BW; Kim JI; Park SH; Kim JK; Han SW; Jung IS; Sun HS; Lee AW; Lee KY
Korean J Gastroenterol; 2005 Sep; 46(3):189-95. PubMed ID: 16179838
[TBL] [Abstract][Full Text] [Related]
10. Polypoid dysplasia in Barrett's esophagus: a clinicopathologic, immunohistochemical, and molecular study of five cases.
Thurberg BL; Duray PH; Odze RD
Hum Pathol; 1999 Jul; 30(7):745-52. PubMed ID: 10414492
[TBL] [Abstract][Full Text] [Related]
11. Biologic properties of columnar epithelium underneath reepithelialized squamous mucosa in Barrett's esophagus.
Hornick JL; Blount PL; Sanchez CA; Cowan DS; Ayub K; Maley CC; Reid BJ; Odze RD
Am J Surg Pathol; 2005 Mar; 29(3):372-80. PubMed ID: 15725807
[TBL] [Abstract][Full Text] [Related]
12. Analysis of Ki-67, p53 and Bcl-2 expression in the dysplasia-carcinoma sequence of Barrett's esophagus.
Rioux-Leclercq N; Turlin B; Sutherland F; Heresbach N; Launois B; Campion JP; Ramee MP
Oncol Rep; 1999; 6(4):877-82. PubMed ID: 10373674
[TBL] [Abstract][Full Text] [Related]
13. Methylene blue staining of dysplastic and nondysplastic Barrett's esophagus: an in vivo and ex vivo study.
Canto MI; Setrakian S; Willis JE; Chak A; Petras RE; Sivak MV
Endoscopy; 2001 May; 33(5):391-400. PubMed ID: 11396755
[TBL] [Abstract][Full Text] [Related]
14. Expression of MUC1 and MUC2 mucin gene products in Barrett's metaplasia, dysplasia and adenocarcinoma: an immunopathological study with clinical correlation.
Chinyama CN; Marshall RE; Owen WJ; Mason RC; Kothari D; Wilkinson ML; Sanderson JD
Histopathology; 1999 Dec; 35(6):517-24. PubMed ID: 10583575
[TBL] [Abstract][Full Text] [Related]
15. Comparison of COX-2, Ki-67, and BCL-2 expression in normal esophageal mucosa, Barrett's esophagus, dysplasia, and adenocarcinoma with postablation mucosa and implications for ablative therapies.
Lewis CJ; Thrumurthy SG; Pritchard S; Armstrong G; Attwood SE
Surg Endosc; 2011 Aug; 25(8):2564-9. PubMed ID: 21359892
[TBL] [Abstract][Full Text] [Related]
16. COX-2, CDX2, and CDC2 immunohistochemical assessment for dysplasia-carcinoma progression in Barrett's esophagus.
Villanacci V; Rossi E; Zambelli C; Galletti A; Cestari R; Missale G; Casa DD; Bassotti G
Dig Liver Dis; 2007 Apr; 39(4):305-11. PubMed ID: 17307036
[TBL] [Abstract][Full Text] [Related]
17. Patterns of p53 immunoreactivity in non-neoplastic and neoplastic Barrett's mucosa of the oesophagus: in-depth evaluation in endoscopic mucosal resections.
Toon C; Allanson B; Leslie C; Acott N; Mirzai B; Raftopoulos S; Kumarasinghe MP
Pathology; 2019 Apr; 51(3):253-260. PubMed ID: 30826014
[TBL] [Abstract][Full Text] [Related]
18. MN antigen expression in normal, preneoplastic, and neoplastic esophagus: a clinicopathological study of a new cancer-associated biomarker.
Turner JR; Odze RD; Crum CP; Resnick MB
Hum Pathol; 1997 Jun; 28(6):740-4. PubMed ID: 9191010
[TBL] [Abstract][Full Text] [Related]
19. Survivin, a potential biomarker in the development of Barrett's adenocarcinoma.
Vallböhmer D; Peters JH; Oh D; Kuramochi H; Shimizu D; Demeester SR; Hagen JA; Chandrasoma PT; Danenberg KD; DeMeester TR; Danenberg P
Surgery; 2005 Oct; 138(4):701-6; discussion 706-7. PubMed ID: 16269299
[TBL] [Abstract][Full Text] [Related]
20. Expression of the putative stem cell marker Musashi-1 in Barrett's esophagus and esophageal adenocarcinoma.
Bobryshev YV; Freeman AK; Botelho NK; Tran D; Levert-Mignon AJ; Lord RV
Dis Esophagus; 2010 Sep; 23(7):580-9. PubMed ID: 20459440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
